Ananda Developments - Change of Location for General Meeting
Announcement provided by
Ananda Developments Plc · ANA08/10/2024 10:50
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Change of Location for General Meeting (GM)
Ananda Developments plc (AQSE: ANA), a life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions, announces that the location of the upcoming General Meeting (GM), previously scheduled to be held at 2.00pm today at the offices of Shakespeare Martineau LLP, 60 Floor, 60 Gracechurch Street,
Due to unforeseen security concerns and the closure of the current venue, we have made the decision to move the GM to a new location to ensure the safety and comfort of all attendees.
The GM will now take place at:
40 Gracechurch Street,
Date and time of the GM remain unchanged.
We apologise for any inconvenience this may cause and appreciate your understanding as we prioritize the safety of our shareholders and stakeholders.
Please ensure that you update your records with the new venue information. Should you have any questions or require further assistance, please contact our investor relations team at ir@anandadevelopments.com.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
For more information please contact:
InvestorHub Engage with us directly at Ananda Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Finance Director Jeremy Sturgess-Smith |
+44 (0)7463 686 497 ir@anandadevelopments.com |
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe |
+44 (0)20 3470 0470 |
Corporate Broking Abigail Wayne Rob Rees |
|
Yellow Jersey PR Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.
For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/mPqxKr
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.